IRIS
BORDI, Paola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.094
AS - Asia 2.972
EU - Europa 1.841
SA - Sud America 475
AF - Africa 168
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 4
Totale 8.560
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.010
SG - Singapore 1.054
CN - Cina 686
VN - Vietnam 539
IT - Italia 469
BR - Brasile 361
SE - Svezia 287
IE - Irlanda 274
HK - Hong Kong 271
DE - Germania 167
FR - Francia 136
ZA - Sudafrica 106
NL - Olanda 105
IN - India 81
RU - Federazione Russa 77
GB - Regno Unito 64
AT - Austria 63
FI - Finlandia 59
BD - Bangladesh 48
AR - Argentina 44
CA - Canada 43
TR - Turchia 38
ID - Indonesia 36
JP - Giappone 29
PH - Filippine 25
IQ - Iraq 23
KR - Corea 23
ES - Italia 21
MX - Messico 21
CO - Colombia 18
EC - Ecuador 18
CI - Costa d'Avorio 17
PK - Pakistan 17
CZ - Repubblica Ceca 16
BE - Belgio 15
UA - Ucraina 15
PL - Polonia 14
UZ - Uzbekistan 13
IR - Iran 12
TN - Tunisia 12
MA - Marocco 11
VE - Venezuela 11
CL - Cile 10
LT - Lituania 10
TH - Thailandia 9
JO - Giordania 8
SA - Arabia Saudita 8
TW - Taiwan 8
EG - Egitto 7
KZ - Kazakistan 7
AU - Australia 6
LU - Lussemburgo 6
MY - Malesia 6
AL - Albania 5
AZ - Azerbaigian 5
DO - Repubblica Dominicana 5
IL - Israele 5
BG - Bulgaria 4
CR - Costa Rica 4
ET - Etiopia 4
GR - Grecia 4
NP - Nepal 4
OM - Oman 4
PY - Paraguay 4
DK - Danimarca 3
KE - Kenya 3
MD - Moldavia 3
PE - Perù 3
PT - Portogallo 3
RO - Romania 3
SN - Senegal 3
XK - ???statistics.table.value.countryCode.XK??? 3
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
CH - Svizzera 2
GY - Guiana 2
HU - Ungheria 2
JM - Giamaica 2
KG - Kirghizistan 2
LV - Lettonia 2
NO - Norvegia 2
PA - Panama 2
QA - Qatar 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
BB - Barbados 1
BO - Bolivia 1
BY - Bielorussia 1
CG - Congo 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
DZ - Algeria 1
GE - Georgia 1
GT - Guatemala 1
IS - Islanda 1
KH - Cambogia 1
Totale 8.549
Salva come PNG Salva come JPEG
Città #
Singapore 599
Ashburn 497
Dallas 349
Chandler 302
San Jose 276
Dublin 270
Hong Kong 258
Beijing 166
Santa Clara 165
Ho Chi Minh City 156
Hanoi 126
Boardman 117
Parma 103
Johannesburg 102
New York 99
Los Angeles 96
Shanghai 88
Munich 84
Lauterbourg 67
Ann Arbor 60
Milan 52
Vienna 51
Princeton 46
Bologna 42
Hefei 39
Moscow 36
São Paulo 35
Council Bluffs 33
Marseille 31
Helsinki 29
Chicago 28
Des Moines 28
Columbus 25
Nanjing 25
Wilmington 25
Frankfurt am Main 22
Haiphong 22
Buffalo 21
Da Nang 20
Tokyo 20
Turku 20
Verona 20
Atlanta 19
Seattle 19
The Dalles 19
Denver 18
Jakarta 18
Abidjan 17
Bremen 17
Dearborn 17
Montreal 17
Nuremberg 16
Seoul 16
Rome 15
Izmir 14
Amsterdam 13
Biên Hòa 13
Chennai 13
Guangzhou 13
Jinan 13
London 13
Istanbul 12
Modena 12
Redondo Beach 12
Warsaw 12
West Jordan 12
Brno 11
Poplar 11
Bengaluru 10
Brooklyn 10
Changsha 10
Hải Dương 10
Rio de Janeiro 10
Brasília 9
Brussels 9
Redmond 9
Stockholm 9
Tashkent 9
Tianjin 9
Trento 9
Amman 8
Baghdad 8
Chongqing 8
Lahore 8
Manchester 8
Phoenix 8
Pune 8
Belo Horizonte 7
Boston 7
Houston 7
Kunming 7
Mexico City 7
Mumbai 7
Orem 7
Quảng Ngãi 7
Toronto 7
Buenos Aires 6
Curitiba 6
Dhaka 6
Düsseldorf 6
Totale 5.288
Salva come PNG Salva come JPEG
Nome #
1328P Dynamic blood immune-inflammatory and radiomic profiling to decode distinct patterns of acquired resistance to immunotherapy in NSCLC patients 214
227P Sexual dimorphism in immune profile of early and advanced NSCLC 200
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy 198
The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors 189
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC 176
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC 175
LONGITUDINAL MONITORING OF RADIOMIC AND BLOOD IMMUNE-INFLAMMATORY DESCRIPTORS AS A NON-INVASIVE APPROACH TO PREDICT ICI EFFICACY IN ADVANCED NSCLC PATIENTS 174
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients 170
CLINICAL PREDICTORS OF 30-DAY MORTALITY IN HOSPITALIZED PATIENTS WITH LUNG CANCER: A RETROSPECTIVE SINGLE-CENTER OBSERVATIONAL STUDY 167
Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 164
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 160
Widespread Nivolumab-induced Enteropathy in a Long Responder Non–Small-cell Lung Cancer Patient 160
Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature 157
2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients 156
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 153
From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC 152
Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC 144
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 144
Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first-line immunotherapy-based regimens 140
Emergence of a HER2-amplified clone during disease progression in an ALK-rearranged NSCLC patient treated with ALK-inhibitors: A case report 138
Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with Nivolumab 137
Sarcoid-like reaction mimicking disease progression in an ALK-positive lung cancer patient receiving lorlatinib 135
Monitoring cfDNA in plasma and in other liquid biopsies of advanced EGFR mutated NSCLC patients: A pilot study and a review of the literature 135
5P Blood immune-inflammatory dynamic unveils distinctive irAE features in ICI treated NSCLC 133
Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer 132
Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs) 131
1061P Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC 130
ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin 129
1599P Clinical predictors of 30-day mortality in hospitalized patients with lung cancer: A retrospective single-center observational study 127
2125P Potential ROle of hypoVItaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): A prospective observational study 126
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 125
P1.15-04 Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 124
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The practice study 124
2PD Monitoring of secondary drug resistance mutations in circulating tumor DNA of patients with advanced ALK positive NSCLC 123
Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer 120
Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy 118
Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: A study on circulating tumor DNA 117
Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment 116
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% 113
Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study 112
A case series of non-small cell lung cancer patients with EGFR or HER2 exon 20 insertion in Li Fraumeni syndrome 109
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 108
L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC 107
Crizotinib resensitization by compound mutation 102
Thirty-day mortality in hospitalised patients with lung cancer: incidence and predictors 100
EP.15B.05 Predictors of 30-Day Mortality after Systemic Therapy in Hospitalized Lung Cancer Patients: A Retrospective Single-Center Observational Study 99
Longitudinal blood immune-inflammatory and radiomic profiling to decode different patterns acquired resistance to immunotherapy in patients with NSCLC 97
NGS detection of gene rearrangements and METexon14 mutations in liquid biopsy of advanced NSCLC patients: A study of two Italian centers 97
Prognostic immunoinflammatory and transcriptomic profiles in patients with pleural mesothelioma undergoing immunotherapy 96
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients 94
Dynamic evaluation of circulating mirna profile in egfr‐ mutated nsclc patients treated with egfr‐tkis 93
Narrative literature and cancer: improving the doctor-patient relationship 91
Liquid Biopsy and 18F-FDG PET/CT Derived Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC 89
P57.08 High Performance Radiomic Classifier to Predict the Response to Immunotherapy in Advanced NSCLC 89
Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study 88
Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study 88
Circulating tumor DNA dynamic variation predicts sotorasib efficacy in KRASp.G12C-mutated advanced non-small cell lung cancer 87
Transient asymptomatic pulmonary opacities and interstitial lung disease in EGFR-mutated non-small cell lung cancer treated with osimertinib 78
Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: Review on emerged mechanisms of resistance 76
Type 2 diabetes mellitus and efficacy outcomes from immune checkpoint blockade in patients with cancer 75
Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian study 71
Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients 70
Dissecting the impact of Controlling Nutritional Status (CONUT) score on survival outcomes and immune-inflammatory profiles in patients with advanced NSCLC undergoing first-line immunotherapy 67
Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: Patient selection and perspectives 67
A prospective study on clinicians’ attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020) 66
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: Implications for personalised treatment 65
Gene mutations in small-cell lung cancer (SCLC): Results of a panel of 6 genes in a cohort of Italian patients 64
Enteral administration of tkis: Report of a response to ceritinib in an alk-positive nsclc patient and literature review 63
Emerging role of gefitinib in the treatmentof non-small-cell lung cancer (NSCLC) 63
Overcoming T790M-driven acquired resistance to EGFR-TKIs in NSCLC with afatinib: A case report 61
Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study 59
Genetic, tissue and circulating PD-L1 profiling to predict the response to immuno-checkpoint inhibitors in advanced NSCLC 56
Metabolic complete response with vinflunine as second-line therapy in a kidney-transplanted patient with advanced urothelial carcinoma: A case report 55
Radiotherapy of non-small-cell lung cancer in the era of EGFR gene mutations and EGF receptor tyrosine kinase inhibitors 50
Efficacy and safety of long-term tolvaptan treatment in a patient with SCLC and SIADH 49
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed 48
Totale 8.675
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.324
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.324
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202114 0 0 0 0 0 0 0 0 0 5 4 5
2021/2022255 2 10 6 17 5 6 48 16 8 4 25 108
2022/20231.119 128 140 58 93 115 120 16 65 311 4 51 18
2023/2024632 30 29 20 22 52 133 67 42 42 44 44 107
2024/20251.868 50 115 160 142 147 180 137 81 169 173 145 369
2025/20264.371 373 343 697 490 588 258 442 232 636 312 0 0
Totale 8.675